Los Angeles Capital Management LLC Sells 1,234 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Los Angeles Capital Management LLC lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 70.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 526 shares of the biopharmaceutical company’s stock after selling 1,234 shares during the period. Los Angeles Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $375,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of REGN. Rakuten Securities Inc. increased its position in shares of Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 19 shares in the last quarter. FSA Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals during the 3rd quarter worth $26,000. Truvestments Capital LLC purchased a new position in Regeneron Pharmaceuticals during the 3rd quarter worth $39,000. Valley Wealth Managers Inc. acquired a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at about $49,000. Finally, Larson Financial Group LLC raised its stake in Regeneron Pharmaceuticals by 127.3% in the third quarter. Larson Financial Group LLC now owns 50 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 28 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 2.0 %

REGN stock opened at $684.87 on Tuesday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $642.00 and a 52-week high of $1,211.20. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The firm has a market cap of $74.87 billion, a P/E ratio of 17.89, a PEG ratio of 2.34 and a beta of 0.08. The company’s 50-day simple moving average is $697.91 and its 200-day simple moving average is $862.68.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $11.86 earnings per share. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be paid a $0.88 dividend. The ex-dividend date is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.51%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Wells Fargo & Company cut their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price target for the company from $762.00 to $834.00 in a research note on Wednesday, February 5th. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Sanford C. Bernstein cut their target price on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. Finally, UBS Group lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $1,130.00 to $738.00 in a research note on Thursday, January 16th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.